Bristol-Myers Squibb
BMYBristol-Myers Squibb is a global biopharmaceutical company focused on the discovery, development, and delivery of transformational medicines for patients facing serious diseases.
Earnings
Next report
Oct 29, 2026 (in 2 months)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Bristol-Myers Squibb is a global biopharmaceutical company focused on the discovery, development, and delivery of transformational medicines for patients facing serious diseases. The company combines the scale of a major pharmaceutical firm with the innovation-driven focus of biotechnology to address high-need therapeutic areas including oncology, hematology, immunology, and cardiovascular health.
A leading global biopharmaceutical entity with a dominant presence in oncology and cardiovascular medicine, characterized by high R&D investment and strategic acquisitions.
FAQ
- What is Bristol-Myers Squibb's market cap?
- Bristol-Myers Squibb (BMY) has a market capitalization of $138.03B and trades on NYSE.
- What is Bristol-Myers Squibb's revenue and profitability?
- Bristol-Myers Squibb generated $49.2B in trailing twelve-month revenue with net income of $9.3B, representing a net margin of 18.9%. Gross margin stands at 70.2%, with free cash flow of $11.4B. These figures are based on the Q2 2026 filing.
- Who are Bristol-Myers Squibb's competitors?
- Bristol-Myers Squibb's key competitors include Merck & Co., Johnson & Johnson, ABBVIE INC., and others. These companies compete in similar markets and product categories.
- Who does Bristol-Myers Squibb partner with?
- Bristol-Myers Squibb's notable partners include Pfizer Inc..
- What subsidiaries does Bristol-Myers Squibb have?
- Bristol-Myers Squibb's subsidiaries include Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and others.
- Where is Bristol-Myers Squibb headquartered?
- Bristol-Myers Squibb is headquartered in United States of America and employs approximately 34,100 people. It has been publicly traded since 1952.
